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Abstract
Human embryonic stem cells (hESCs) and induced pluripotent cells (iPSCs) have the potential to differentiate into
any somatic cell, making them ideal candidates for cell replacement therapies to treat a number of human diseases
and regenerate damaged or non-functional tissues and organs. Key to the promise of regenerative medicine is
developing standardized protocols that can safely be applied in patients. Progress towards this goal has occurred
in a number of fields, including type 1 diabetes mellitus (T1D). During the past 10 years, significant technological
advances in hESC/iPSC biochemistry have provided a roadmap to generate sufficient quantities of glucose-
responsive, insulin-producing cells capable of eliminating diabetes in rodents. Although many of the molecular
mechanisms underlying the genesis of these cells remain to be elucidated, the field of cell-based therapeutics to
treat T1D has advanced to the point where the first Phase I/II trials in humans have begun. Here, we provide a
concise review of the history of cell replacement therapies to treat T1D from islet transplantations and
xenotranplantation, to current work in hESC/iPSC. We also highlight the latest advances in efforts to employ
insulin-producing, glucose-responsive β-like cells derived from hESC as therapeutics.
Background
There remains an urgent and critical need for new treat-
ments for type 1 diabetes (T1D). A current prevailing
hypothesis is that cell replacement for pancreatic β-cells
destroyed by autoimmune attack will optimally restore
euglycemia. While efforts to augment endogenous popu-
lations of a patient’s residual β-cells or pancreatic spe-
cific stem cells remains an active avenue of research,
efforts to enhance proliferation of these populations of
cells without further autoimmune damage has had limited
success. Conversely, the development of in vitro generated
populations of insulin-producing, glucose-responsive cells
has overcome many significant challenges, including
generation of chemically defined conditions for reprodu-
cibly differentiating hESCs into endocrine precursors
(EPs) and, the development of strategies to purify these
precursor cells to avoid the development of benign tumors
such as teratomas. With the basic protocols in place other
pressing issues will move to the forefront, including
prevention of cell destruction following transplantation,
encapsulation, and the application of newer anti–rejection
therapies.
Islet transplantation as a treatment for T1D – a historical
perspective
The modern age of islet transplantation was ushered in
by pioneering studies of Lacy and Kostianovsky who de-
veloped a method to isolate and purify islets from rat
pancreas [1]. Building upon this work, Kemp and col-
leagues demonstrated that direct injection of freshly iso-
lated pancreatic islets into the portal vein of rats with
streptozotocin-induced diabetes was able to restore
normoglycemia [2]. Subsequently, the same protocol was
found to be effective in diabetic rhesus monkeys [3]. In
1990, the first successful human clinical islet transplanta-
tions were performed [4]. However, only a small number
of patients were able to maintain long term euglycemia.
Until the publication of the “Edmonton protocol” [5] in
the year 2000, the prognosis for maintaining insulin inde-
pendence was less than 10 % at 1-year post procedure.
The Edmonton group brought about hope that their
results −100 % in 7 patients-would last more than 1 year.
Further follow up showed that after 5 years the rate of
insulin-independence was down to 10 %. In the last
5 years, refinements in islet isolation and newer
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immunosuppressive agents offer a 50 % possibilities of
success for up to 5 years post-transplant [6]. More re-
cently, Moassesfar and colleagues have compared results
from islet vs. pancreas transplantation and found that, in
terms of insulin independence after 3 years post-
transplantation, both approaches were approximately
70 % efficient [7]. Although significant hurdles remain
with immunosuppression and the availability of donated
pancreases to treat patients with T1D, recent advances in
the field are encouraging for overcoming these two prob-
lems. Patients who received combinatorial treatment with
both T-cell depleting anti-thymocyte globulin (ATG) and
the TNFα inhibitor etanercept had dramatically higher
rates of insulin independence at 3 and 5 years after final
infusion compared with patients treated with T-cell de-
pleting antibodies alone or with the traditional standard
IL2 receptor antibodies [8]. Recently, application of the
Clinical Islet Transplantation 07 (CIT07) protocol
demonstrated improvedβ-cell secretory capacity, indi-
cating an increased functional islet β-cell mass. The
CIT07 protocol incorporates T-cell depletion and
TNFα inhibition described above with inhibitor main-
tenance therapies described in the original Edmonton
protocol [9].
Alternate sources for islet transplantation
Expanded populations of human β-cells and human fetal
pancreatic cells
Over 20 years ago, our laboratory identified the combin-
ation of hepatocyte growth factor/scatter factor (HGF/SF)
and the HTB-9 extracelluar matrix from human bladder
carcinoma cells, as potent stimuli for β cell replication
[10]. Cells could remain in culture over 15 doublings, but
with time, both insulin mRNA and protein levels dropped
precipitously. Although PDX1 expression was maintained,
significant production of insulin was not observed after
transplantation. Loss of β cell phenotype was found to be
associated with epithelial-to-mesenchymal transition
(EMT) [11]. In the past few years, exciting work has fo-
cused on the ability to reverse EMT by mesenchymal-to-
epithelial transition (MET) through modulation of TGFβ
and NOTCH signaling in low passage β-cells [12–14].
miR-375, a microRNA previously implicated in both de-
finitive endoderm formation and islet function [15, 16],
was identified as critical regulator of MET and β-cell de-
differentiation [17]. Viral expression of miR-375 in ex-
panded β-cells increased expression of the epithelial
marker E-cadherin, as well as the islet/β-cell transcription
factors PDX1, MAFA, and NEUROD1. In cells treated
with a miR-375 virus, expression of the mesenchymal
markers N-cadherin and vimentin decreased. Together,
these studies represent significant strides in understanding
the underlying biochemistry that regulates β-cell expan-
sion and temporal gene expression.
Investigations using human fetal pancreatic cells from
the mid 1980s to the 1990s first provided evidence that
human fetal tissues could be manipulated in vitro to ad-
vance differentiation to β-cells from endocrine precur-
sors previously identified in experiments performed
during pancreas development in rodents. Full appropri-
ate response to glucose in terms of insulin release was
not obtained until the cells were transplanted into
immune-deficient mice for periods of 10 to 12 weeks
[18–21]. These observations proved valuable to the un-
derstanding of the new cell supply derived from human
stem cells as discussed below.
Although much has been published about the poten-
tial for β-cell regeneration through replication of existing
β-cells and/or differentiation from putative precursors,
clinical protocols for their use are not available since the
positive results reported in small animals models have
not been possible to translate to humans.
Pancreatic exocrine cell reprogramming
Abnormalities of the exocrine pancreas in T1D have
been described since 1940 but still scant attention has
focused on research in this area. A recent review de-
scribes subclinical exocrine dysfunction associated with
the characteristic findings in the islets of T1D subjects,
but it remains unclear whether the two are related to
the autoimmune response after the onset of T1D [22].
Because the pancreatic exocrine cells share a similar
microenvironment and lineage with endocrine pancre-
atic cells, they are prime targets for reprogramming and
therapeutic use in humans. In 2000, Bonner-Weir and
colleagues reported that in vitro human adult ductal tis-
sue cultured on Matrigel for 4 weeks increased insulin
content by 10–15 fold. Upon glucose challenge, the cells
secreted insulin [23]. In follow-up studies, adenoviral in-
fection of pancreatic endocrine cells with the transcrip-
tion factors (PDX1, NGN3, NEUROD, or PAX4) was
found to induce insulin transcription [24]. In vivo repro-
gramming of pancreatic exocrine cells in mice using
PDX1, NGN3, and MAFA were found to be functionally
equivalent to β-cells and able to ameliorate hypergly-
cemia [25]. Recent work from Lemper and colleagues
found that human pancreatic exocrine cells, when trans-
duced with MAPK and STAT3, activated expression of
NGN3. Expression of insulin was limited to cells grown
under the initial conditions [26]. Advances in repro-
gramming of mouse and human pancreatic exocrine
cells in the absence of genetic manipulation were re-
ported by Baeyens and Klein [27, 28]. In the first study,
mouse ascinar cells were converted to β-like cells upon
incubation with EGF (epidermal growth factor) and
CNTF (ciliary neurotrophic factor). These cells were
functional, glucose responsive, and restored normal gly-
cemia for extended periods. Similar to the work of
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Lemper, this study identified STAT3 as a critical regula-
tor of this process. In the second study, BMP-7 (bone
morphogenic protein 7) was found to induce conversion
of human adult pancreatic nonendocrine pancreatic tis-
sue into endocrine-like cells with elevated insulin con-
tent and that were glucose responsive in vitro and after
transplantation. The recent successes in these systems and
the abundance of exocrine cells suggest a potentially
therapeutic relevant cell population to treat T1D patients.
However, clinical use of these cells is hampered by safe
and effective targeting of reprogramming transcription
factors and control of their activity once in selected cells.
Xenotransplantation
Xenotransplantation provides another alternative for the
limited supply issue faced from the too few human islets
available from donated human pancreases. In 2006, two
groups reported long-term survival of porcine islets in
non-human primates [29, 30]. Recently, Shin et al. dem-
onstrated that pig islet grafts survived for greater than
6 months and were able to maintain normoglycemia
for >6 months in four immunosuppressed non-human
primates [31]. Given issues of supply and demand, porcine
islet xenotransplantation for T1D now appears to be a
therapeutic consideration following extensive preclinical
investigations, suggesting that clinical trials may be now
justified. Two current reviews provide in-depth insight
into the advances and shortcomings in this field [32, 33].
hESCs
An effective cell-based therapeutic for T1D requires cells
that sense glucose fluctuations and respond with appro-
priate insulin secretion. While islet transplantation has
shown promise as a treatment for type T1D, a major
obstacle to this approach is the shortage of the islets
containing insulin-producing cells. Over the past decade,
hESCs/iPSCs have emerged as promising sources for the
pancreatic β-cells lost in T1D. hESCs are characterized
by their capacity for self-renewal and differentiation to
almost any specific cell type in the human body. The
first study demonstrating functional and meaningful
secretion of insulin after transplantation into mice of β-
cells generated from hESC was published in 2008 [34],
less than 10 years after the initial reports on spontaneous
in vitro differentiation of hESC into insulin producing
cells [35]. The advent of iPSCs in 2007 by Takahashi and
Yamanaka [36, 37] opened the possibility of reprogram-
ming a patient’s own fibroblasts into β-cells for use in
clinical situations, including T1D. Since the initial publica-
tions, this patient-specific approach towards treatment of
various diseases has allowed researchers to address the
effect of point mutations, gene deletions, or translocations
on the function of a cell in culture or in a model animal
system.
Although critical gaps in the understanding of the
molecular mechanisms that drive the genesis of insulin
producing cells from hESCs/iPSCs exist, many of the es-
sential growth factors and inhibitors have been identi-
fied. Below, we briefly highlight the various steps in
hESC differentiation toward glucose-responsive, insulin
secreting cells.
Maintenance of pluripotency and definitive endoderm
formation (DE) Pluripotency of hESCs initially required
co-culture with a fibroblast feeder layer that secreted un-
identified soluble factors that helped maintain pluripo-
tency. Unlike mouse ES cells, hESC were unable to
maintain pluripotency by incubation with leukemia in-
hibitor factor (LIF) [38]. In 2005, Beattie et al. identified
low levels of activin A as critical factor secreted by
feeder layers that maintained pluripotency [39]. Later, it
was determined that elevated activin A levels, combined
with inhibition of PI 3-kinase signaling was required for
efficient DE formation [40, 41].
Glucose-responsive, insulin producing cells from DE
Over the past decade many different groups have con-
tributed to generate differentiation protocols that mimic
pancreas development (reviewed by van Hoof, et al.
[42]). From the seminal studies on DE formation, several
protocols were published for the generation of insulin
producing cells, mimicking the extensive knowledge ac-
quired on pancreatic development in Xenopus and ro-
dents [34, 43, 44]. Large populations of cells were
obtained expressing transcription factors present in pan-
creatic endoderm, including PDX1 and NGN3. However,
a large percentage of the cells were poly-hormonal, sim-
ultaneously expressing somatostatin, glucagon and/or in-
sulin. Expression of multiple hormone markers within a
single cell and findings indicating poor response to
glucose in terms of insulin release, suggested that the
protocols required further refinements. Hrvatin et al.
employed mRNA profiling to demonstrate that insulin-
expressing cells derived from hESCs are more similar to
human fetal pancreatic cells than mature β-cells [45].
ViaCyte, a biotechnology company in San Diego, CA
was instrumental in the development of protocols to
generate glucose-responsive, insulin secreting cells from
hESC, circumvented these issues by transplanting pan-
creatic progenitor cells into mice which subsequently
matured into functional β-like cells in vivo capable of
protecting against streptozotocin-induced hyperglycemia
[34]. In more recent work form the same group, the
pancreatic progenitor cells were further differentiated
into islet-like cells that contained a high percentage
(~80 %) endocrine cells, of which about half expressed
insulin [46]. Recently, three refined protocols for gener-
ating glucose-responsive, insulin-producing cells have
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been published by Pagliuca et al. [47], Rezania et al. [48],
and Russ et al. [49]. In all protocols, cells are cultured in
suspension (3D culture) which better mimics the condi-
tions for in vivo growth and differentiation. Although
there is considerable variance between the protocols
during formation of definitive endoderm, primitive gut
tube, and posterior foregut formation, the culture condi-
tions to drive cells from pancreatic endocrine precursors
to immature β-cells and finally to mature β-cells is re-
markably similar between the last 3 reports (Rezania,
Pagliuca, and Russ). Specifically, each protocol requires
retinoic acid to dampen the sonic hedgehog signaling
pathway, a known inhibitor of pancreas development
[50]. Additionally, each protocol uses the ATP competi-
tive Alk5 inhibitor II to signaling through TGFβ RI sig-
naling and LDN193189/Noggin to block signaling
through BMP Type I receptors. Finally, both the Rezania
and Pagliuca protocols require the thyroid hormone tri-
iodothyronine (T3), which has previously been shown to
be required for liver development [51]. Sixteen to twenty
weeks post engraftment, the CyT49/VC-01 cells from
the ViaCyte protocol had matured in vivo to become
pancreatic endoderm cells that were able to protect
against streptozotocin (STZ)-induced hyperglycemia
[52]. Similarly, diabetes was reversed approximately
6 weeks after transplantation using the Rezania protocol
[48]. hESCs differentiated using the Pagliuca protocol
were found to secrete human insulin in response to a
glucose challenge after transplantation in a manner that
prevented hyperglycemia in the Akita mouse [47]. β-like
cells derived from the Russ protocol were able to reduce
blood glucose levels, after short-term transplantation
under the kidney capsule of nude mice [49].
Careful examination of the similarities and differences
between the four protocols reveals limitations between
the different methods to generate glucose-responsive,
insulin-producing cells from hESCs. Rezania and Pagliuca
relied upon previously established protocols for gener-
ation of primitive gut tube and posterior foregut and pri-
marily focused on optimization of the later stages of
hESC differentiation. Russ found that elimination of
Noggin during posterior foregut formation (high retinoic
acid levels) followed by combined treatment with EGF/
KGF enhanced PDX1/NKX6.1 expression and reduced
the number of polyhormonal cells. This work empha-
sizes the importance of temporal activation of signaling
pathways during hESC differentiation.
Encapsulation of hESC for transplantation Reprodu-
cible protocols to generate cells that can ablate diabetes
in mice have led to questions about how these cells can
be used therapeutically. Similar to the situation with is-
lets, transplanted stem cells also face the problem of re-
jection. Cell encapsulation has been actively pursued as
a means of abrogating rejection by protecting the encap-
sulated cells from the immune system while allowing ad-
equate oxygenation, nutrient delivery, and glucose and
insulin transport across the barrier. Although no success-
ful and reproducible human islet encapsulation lasting
more than a few weeks has been reported in patients with
T1D (See review [53]), ViaCyte has reported that insulin-
producing cells derived from hESC can function in vivo in
their proprietary macro-encapsulation devices [46].
Clinical trials ViaCyte has obtained FDA approval and
initiated a phase I/II clinical trial for the implantation of en-
capsulated endocrine progenitor cells derived from hESCs
from their VC-01cell line. (see https://clinicaltrials.gov/
show/NCT02239354).
Unresolved issues in hESC biology While the general
differentiation protocol to generate pancreatic endoderm
cells has been elucidated, a detailed molecular roadmap
of the signal transduction, transcription factor, and epi-
genetic networks does not yet exist. It is critical to
understand the interplay between growth factors and in-
hibitors during specific stages of differentiation. We have
observed considerable heterogeneity between different
hESC lines in their ability to generate insulin positive
cells from pluripotent cells (King unpublished data). Pre-
liminary data suggests that significant differences in ex-
pression of receptor tyrosine kinases and G-protein
coupled receptors exist on the different cell lines that
significantly alter signaling, proliferation, apoptosis, ex-
pression of transcription factors and epigenetic modifi-
cations. These biochemical differences in cell lines could
have multiple repercussions in the interpretation of re-
sults with clinical trials. ViaCyte has demonstrated a re-
producible in vitro hESC expansion and banking method
for their VC-01 cell line that achieves 50–100 fold ex-
pansion per week [52]. Scalability was also demonstrated
in the differentiation protocols described by Pagliuca
and Russ [47, 49]. However, to date, these are the only
three hESC systems for which this has been demon-
strated. Whether this same expansion without loss of in-
sulin expression can be demonstrated for other hESC
lines or iPSCs remains to be determined as well as the
number of hESCs derived β-cells to effectively amelior-
ate type 1 diabetes in humans.
iPSCs
Like hESCs, iPSCs have infinite self-renewal capacity
and the ability to differentiate into any cell type, provid-
ing the hope of patient-specific cells for therapeutic use.
iPSCs can be generated from virtually any adult somatic
and peripheral blood cell through reprogramming by the
addition of integrating retroviral vectors containing four
pluripotency transcription factors, OCT4, SOX2, KLF4,
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and c-MYC [36]. iPSCs behave similarly to hESCs ex-
pressing multiple markers of pluripotency, have unlim-
ited potential for self-renewal, and can be differentiated
into cells from all three germ layers. Studies utilizing
mouse reprogrammed iPSCs to generate β-cells used a
considerably different protocol from hESCs. However
the differentiated cells, upon transplantation, secreted
insulin in response to glucose and normalized blood glu-
cose levels [54]. To date, iPSCs generated from patients
with T1Dhave used integrating retroviral vectors. Re-
cently, Kudva reported using nonintegrating Sendai viral
vector to reprogram cells from patients with T1D [55],
raising the hope that problems of viral integration into
the host genome could eliminate the risk for develop-
ment of neoplasias.
Barriers to the clinical translation of iPSCs Rediffer-
entiation of iPSCs from diabetic patients into pancreatic
islets has the potential to allow for patient-specific cell
replacement therapy. This field has been recently
reviewed by Neofytou et al. [56], pointing out the chal-
lenges that a research setting would face by embarking
on clinical trials. Briefly summarized, a GMP facility is
required with capacity for characterization assays includ-
ing cell line stability, karyotyping, and differentiation
capacity, expression of pluripotency antigens, purity as-
says and cell type heterogeneity. These efforts represent
a significant monetary allocation that few research insti-
tutions are capable of sustaining. Once the cells have
undergone directed differentiation, following transplant-
ation the possibilities of benign (teratoma) or malignant
(carcinomas) are a safety concern to be dealt with after
rigorous safety and toxicity studies are performed. As is
the case with hESCs, iPSCs may also become immuno-
genic following differentiation protocols, a situation re-
quiring careful studies aimed at creating immune
tolerance before human trials are considered. It has been
calculated that the generation of iPSC-derived tissue
product for clinical use approaches one million dollars
[57]. In their review, Neofytoy at al, also discuss the im-
plications for the use of iPSC HLA-match allogeneic cell
lines banking for commercialization vs. autologous cell
lines that may required FDA regulatory standards even
more difficult to fulfill.
Conclusions
This review has focused upon current state of cell re-
placement therapeutics in T1D. These cells are designed
to function when transplanted into humans without eli-
citing an immune response. While considerable headway
is being made in this respect, other factors that may influ-
ence the progression of type 1 diabetes cannot be ignored.
For example, loss of β-cell function has been observed in
NOD mice before the onset of hyperglycemia [58],
possibly as a response to the combination of autoimmun-
ity and endoplasmic reticulum stress [59]. Whether these
factors play a role in the human system remains to be elu-
cidated. In conclusion, the prospects for a cell based
therapy-using ESC or iPSC in T1D still requires extensive
research for the application of clinical protocols that satis-
fies scientific scrutiny and the FDA.
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